278 related articles for article (PubMed ID: 31187704)
1. Repositioning of HIV Aspartyl Peptidase Inhibitors for Combating the Neglected Human Pathogen Trypanosoma cruzi.
Sangenito LS; Menna-Barreto RFS; d'Avila-Levy CM; Branquinha MH; Santos ALS
Curr Med Chem; 2019; 26(36):6590-6613. PubMed ID: 31187704
[TBL] [Abstract][Full Text] [Related]
2. Repositioning drug strategy against Trypanosoma cruzi: lessons learned from HIV aspartyl peptidase inhibitors.
Sangenito LS; d'Avila-Levy CM; Branquinha MH; Santos ALSD
Mem Inst Oswaldo Cruz; 2022; 117():e210386. PubMed ID: 35293428
[TBL] [Abstract][Full Text] [Related]
3. Decoding the anti-Trypanosoma cruzi action of HIV peptidase inhibitors using epimastigotes as a model.
Sangenito LS; Menna-Barreto RF; D Avila-Levy CM; Santos AL; Branquinha MH
PLoS One; 2014; 9(12):e113957. PubMed ID: 25464510
[TBL] [Abstract][Full Text] [Related]
4. Docking simulation between HIV peptidase inhibitors and Trypanosoma cruzi aspartyl peptidase.
Castilho VVS; Gonçalves KCS; Rebello KM; Baptista LPR; Sangenito LS; Santos HLC; Branquinha MH; Santos ALS; Menna-Barreto RFS; Guimarães AC; d'Avila-Levy CM
BMC Res Notes; 2018 Nov; 11(1):825. PubMed ID: 30463602
[TBL] [Abstract][Full Text] [Related]
5. Nelfinavir and lopinavir impair Trypanosoma cruzi trypomastigote infection in mammalian host cells and show anti-amastigote activity.
Sangenito LS; d'Avila-Levy CM; Branquinha MH; Santos ALS
Int J Antimicrob Agents; 2016 Dec; 48(6):703-711. PubMed ID: 27838277
[TBL] [Abstract][Full Text] [Related]
6. Repurposing strategies for Chagas disease therapy: the effect of imatinib and derivatives against Trypanosoma cruzi.
Simões-Silva MR; De Araújo JS; Peres RB; Da Silva PB; Batista MM; De Azevedo LD; Bastos MM; Bahia MT; Boechat N; Soeiro MNC
Parasitology; 2019 Jul; 146(8):1006-1012. PubMed ID: 30859917
[TBL] [Abstract][Full Text] [Related]
7. High-throughput drug repositioning for the discovery of new treatments for Chagas disease.
Bellera CL; Sbaraglini ML; Balcazar DE; Fraccaroli L; Vanrell MC; Casassa AF; Labriola CA; Romano PS; Carrillo C; Talevi A
Mini Rev Med Chem; 2015; 15(3):182-93. PubMed ID: 25769967
[TBL] [Abstract][Full Text] [Related]
8. Target-based Screening of the Chagas Box: Setting Up Enzymatic Assays to Discover Specific Inhibitors Across Bioactive Compounds.
Salas-Sarduy E; Niemirowicz GT; José Cazzulo J; Alvarez VE
Curr Med Chem; 2019; 26(36):6672-6686. PubMed ID: 31284853
[TBL] [Abstract][Full Text] [Related]
9. HIV aspartic peptidase inhibitors are effective drugs against the trypomastigote form of the human pathogen Trypanosoma cruzi.
Sangenito LS; Gonçalves DS; Seabra SH; d'Avila-Levy CM; Santos AL; Branquinha MH
Int J Antimicrob Agents; 2016 Oct; 48(4):440-4. PubMed ID: 27499433
[TBL] [Abstract][Full Text] [Related]
10. Repositioning of leishmanicidal [1,2,3]Triazolo[1,5-a]pyridinium salts for Chagas disease treatment: Trypanosoma cruzi cell death involving mitochondrial membrane depolarisation and Fe-SOD inhibition.
Martín-Escolano R; Martín-Escolano J; Ballesteros-Garrido R; Cirauqui N; Abarca B; Rosales MJ; Sánchez-Moreno M; Ballesteros R; Marín C
Parasitol Res; 2020 Sep; 119(9):2943-2954. PubMed ID: 32607710
[TBL] [Abstract][Full Text] [Related]
11. Repositioned Drugs for Chagas Disease Unveiled via Structure-Based Drug Repositioning.
Adasme MF; Bolz SN; Adelmann L; Salentin S; Haupt VJ; Moreno-Rodríguez A; Nogueda-Torres B; Castillo-Campos V; Yepez-Mulia L; De Fuentes-Vicente JA; Rivera G; Schroeder M
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33233837
[TBL] [Abstract][Full Text] [Related]
12. Repositioning FDA Drugs as Potential Cruzain Inhibitors from Trypanosoma cruzi: Virtual Screening, In Vitro and In Vivo Studies.
Palos I; Lara-Ramirez EE; Lopez-Cedillo JC; Garcia-Perez C; Kashif M; Bocanegra-Garcia V; Nogueda-Torres B; Rivera G
Molecules; 2017 Jun; 22(6):. PubMed ID: 28629155
[TBL] [Abstract][Full Text] [Related]
13. Current advances in drug discovery for Chagas disease.
Scarim CB; Jornada DH; Chelucci RC; de Almeida L; Dos Santos JL; Chung MC
Eur J Med Chem; 2018 Jul; 155():824-838. PubMed ID: 30033393
[TBL] [Abstract][Full Text] [Related]
14. Trypanothione Reductase: A Target for the Development of Anti- Trypanosoma cruzi Drugs.
Vázquez K; Paulino M; Salas CO; Zarate-Ramos JJ; Vera B; Rivera G
Mini Rev Med Chem; 2017; 17(11):939-946. PubMed ID: 28302040
[TBL] [Abstract][Full Text] [Related]
15. Experimental models in Chagas disease: a review of the methodologies applied for screening compounds against Trypanosoma cruzi.
Fonseca-Berzal C; Arán VJ; Escario JA; Gómez-Barrio A
Parasitol Res; 2018 Nov; 117(11):3367-3380. PubMed ID: 30232605
[TBL] [Abstract][Full Text] [Related]
16. A cysteine protease inhibitor cures Chagas' disease in an immunodeficient-mouse model of infection.
Doyle PS; Zhou YM; Engel JC; McKerrow JH
Antimicrob Agents Chemother; 2007 Nov; 51(11):3932-9. PubMed ID: 17698625
[TBL] [Abstract][Full Text] [Related]
17. Current trends in the pharmacological management of Chagas disease.
Ribeiro V; Dias N; Paiva T; Hagström-Bex L; Nitz N; Pratesi R; Hecht M
Int J Parasitol Drugs Drug Resist; 2020 Apr; 12():7-17. PubMed ID: 31862616
[TBL] [Abstract][Full Text] [Related]
18. An insight on targets and patented drugs for chemotherapy of Chagas disease.
Duschak VG; Couto AS
Recent Pat Antiinfect Drug Discov; 2007 Jan; 2(1):19-51. PubMed ID: 18221162
[TBL] [Abstract][Full Text] [Related]
19. Targets and Patented Drugs for Chemotherapy of Chagas Disease in the Last 15 Years-Period.
Duschak VG
Recent Pat Antiinfect Drug Discov; 2016; 11(2):74-173. PubMed ID: 27784230
[TBL] [Abstract][Full Text] [Related]
20. In Silico Drug Repositioning for Chagas Disease.
Bellera CL; Alberca LN; Sbaraglini ML; Talevi A
Curr Med Chem; 2020; 27(5):662-675. PubMed ID: 31622200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
